A practical reference on mass spectrometry: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-01-23 and is reviewed periodically as new material appears.
The compound circulates in the literature as a research reagent rather than an approved therapeutic. Regulatory agencies in several countries have not authorized it for medical use, and sporting bodies list related thymosin beta-4 peptides among prohibited substances. Suppliers typically market it with a purity figure and a certificate of analysis, while peer-reviewed clinical reports remain sparse. Discussions therefore often separate laboratory findings from anecdotal reports, and reviewers tend to note the small size and methodological limits of the available studies.
TB-500 refers to a synthetic peptide fragment derived from the actin-binding region of thymosin beta-4, a protein present in most mammalian cells. The full protein contains forty-three amino acids, while the commonly sold fragment is a much shorter acetylated sequence, often cited as LKKTETQ. The fragment retains part of the actin-binding motif but lacks the remainder of the parent protein. Material sold under this name is usually lyophilized powder intended for laboratory research, and it is not a finished pharmaceutical product.
Thymosin beta-4 was isolated from calf thymus in the early 1980s and later characterised as an abundant intracellular actin-sequestering protein. Interest in short synthetic fragments grew once the actin-binding motif had been mapped to the middle of the sequence. TB-500 came out of that line of work as a truncated analogue rather than a natural isolate, and it is now sold mainly to laboratories. Published studies on the fragment have been largely in vitro or in animal models, and controlled human trials remain sparse, so claims about effects in people rest on extrapolation.
Literature and online discussion often conflate TB-500 with full-length thymosin beta-4, even though the two differ in size and are not interchangeable in analytical terms. The fragment is produced by solid-phase peptide synthesis, and the product is a defined seven-residue chain rather than a biological extract. Because the term is a trade-style label, two vendors may supply materials of the same nominal sequence but different counter-ion content, purity, or water content. Comparisons across studies are therefore difficult unless the exact sequence and purity are reported.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized solid as supplied |
| Water solubility | Soluble | Dissolves in aqueous media |
| Typical storage temperature | -20 °C | Dry powder, desiccated, protected from light |
| Typical analytical method | RP-HPLC with mass spectrometry | Purity from peak area; mass for identity |
| Common synonyms | Tβ4 fragment; thymosin beta-4 fragment | Naming varies by supplier and catalogue |
Lyophilized TB-500 is hygroscopic and should be kept dry before use. The usual storage recommendation for the solid is -20 °C, protected from light and moisture. Once dissolved, the peptide is less stable, and repeated freeze-thaw cycles can promote aggregation or degradation. Laboratories often divide a reconstituted solution into single-use aliquots and store them at -80 °C. Exact stability limits depend on buffer, pH, and concentration, so published data do not define a single universal condition.
Identity and purity are checked with chromatographic and mass spectrometric methods. Reverse-phase high-performance liquid chromatography separates the peptide from related impurities, while mass spectrometry confirms the expected molecular mass. A certificate of analysis may report a purity percentage, but the laboratory should still verify the material independently. Common quality concerns include truncated sequences, deamidation, oxidation, and residual solvents from synthesis. Because TB-500 is short, some impurities can differ from the target by only a few mass units.
Once in solution, short peptides are generally less stable than the dry powder, and repeated freeze-thaw cycles are a common cause of loss. Laboratory guidance usually calls for aliquoting on first dissolution and storing aliquots at -20 °C or below, away from light. Adsorption to plastic and glass surfaces can lower measured concentration, particularly at low concentrations, so container material and buffer choice can affect results. Visible cloudiness, colour change or unexpected precipitate is a signal to re-check the material.
Purity is normally assessed by reversed-phase HPLC, with the main peak reported as a percentage of total peak area, while identity is confirmed by mass spectrometry. Electrospray and MALDI-TOF instruments are both used, and the observed mass is compared with the value calculated from the stated sequence. Ion-exchange or size-exclusion methods appear where aggregation or charge variants are of interest. Water content, counter-ion content and residual trifluoroacetate from purification are separate variables that can shift the measured mass and should be weighed when reading a certificate of analysis.
Research peptides are typically supplied as a white to off-white lyophilised powder in a sealed vial. The dry solid is more stable than a solution and is normally kept refrigerated or frozen until use. Dissolution is usually done in water, phosphate-buffered saline or a similar aqueous medium, depending on the assay. Because the material is hygroscopic and easily contaminated, opening vials in a low-humidity environment and recording the lot number before use are standard laboratory practices.
Interest in the fragment grew during the 1990s and 2000s, when it moved from laboratory work into sports and supplement markets. Anti-doping bodies added thymosin beta-4 fragments to prohibited lists, and a small number of adverse analytical findings have been reported in competition testing. Published controlled human trials remain scarce. Most mechanistic evidence comes from cell culture and animal models, and those studies examine endpoints such as cell migration, wound closure and inflammation markers. That evidence supports research interest but does not establish clinical benefit, and broad regenerative claims should be read as unverified.
TB-500 is a short synthetic peptide sold under a trade name rather than a systematic chemical name. Suppliers usually describe it as a fragment of thymosin beta-4 and ship it as a lyophilised powder intended for laboratory use. Because the label is commercial, the exact sequence attributed to it is not fully consistent across catalogues, and some listings present a seven-residue peptide while others describe related fragments of similar length. It is not an approved medicine in any major jurisdiction, and it is handled as a research chemical.
Thymosin beta-4 itself is a natural peptide of 43 residues found in many cell types and body fluids. Its best-characterised function is binding and sequestering actin monomers, which influences cytoskeletal dynamics. The sequence most often associated with TB-500, LKKTETQ, corresponds to part of that actin-binding region. A different fragment, Ac-SDKP, is also derived from the same parent peptide and is studied in its own right, which is one reason discussions of thymosin fragments can become confusing. The two are structurally distinct and are not interchangeable.
Discussion of TB-500 appears in several distinct literatures that rarely cite one another. Peer-reviewed studies usually describe in vitro assays or small animal experiments and are cautious about extrapolation. Veterinary and sports communities circulate anecdotal reports with limited methodological detail. Commercial listings add a third layer, often using the name interchangeably with thymosin beta-4 even though the two molecules differ in size and sequence. Regulatory status varies by country, and the compound is not a licensed medicine in most jurisdictions, so readers comparing sources should check which molecule and which purity each source actually describes.
TB-500 is a synthetic seven-residue peptide whose sequence, LKKTETQ, matches the N-terminal actin-binding region of thymosin beta-4. It is usually supplied in an N-terminally acetylated form, a modification that blocks the free amino terminus and can influence behavior in solution. In the research literature the same sequence appears under several names, including thymosin beta-4 fragment and shortened thymosin beta-4. Because it is a short peptide rather than the full 43-residue parent protein, its measured properties differ from those reported for thymosin beta-4 as a whole, and the two are not interchangeable in experimental design.
== O == Severo Ochoa (1905–1993). Spanish and American biochemist at New York University, major contributor to elucidating the genetic code. Nobel Prize in Physiology or Medicine (1959). Member Natl. Acad. Sci. USA. Alexander George Ogston FRS (1911–1996). British biochemist at Oxford University, known for the three-point attachment explanation of how an achiral substance can have a chiral product in the tricarboxylate cycle. Reiji Okazaki (1930–1975). Japanese molecular biologist at Nagoya University, known for discovering Okazaki fragments, an essential step for understanding DNA replication. Tsuneko Okazaki (b. 1933). Japanese molecular biologist at Nagoya University, known for discovering Okazaki fragments, an essential step for understanding DNA replication. L'Oréal-UNESCO Award for Women in Science. Joan Oró (1923–2004). Spanish biochemist at the University of Houston. Prominent for studies of the origin of life. Muriel Wheldale Onslow (1880–1932). British biochemist at Cambridge University, pioneer in biochemical genetics who worked on petal colour in flowers. Alexander Oparin, (1894–1980). Soviet biochemist at Moscow State University, known for his theory on the origin of life in coacervates. Full Member of the USSR Academy of Sciences. Mary Osborn (b. 1940). English cell biologist at the University of Göttingen known for developing techniques for determining protein molecular masses. Mary Jane Osborn (1927–2019). American biochemist at the University of Connecticut, who worked on lipopolysaccharides, and discovered the mechanism of action of methotrexate.
=== Bag of cement and bag mix === The mass of an old bag of cement was one hundredweight (112 pounds, 51 kg). In the concrete and petroleum industry, however, a bag of cement is defined as 94 lb (43 kg) because it has an apparent volume close to 1 cubic foot (28 litres).
In biochemistry and metabolism, beta oxidation (also β-oxidation) is the catabolic process by which fatty acid molecules are broken down in the cytosol in prokaryotes and in the mitochondria in eukaryotes to generate acetyl-CoA. The acetyl-CoA product of this step of fatty acid metabolism enters the citric acid cycle, generating NADH and FADH2, which are electron carriers used in the electron transport chain. It is named as such because the beta carbon of the fatty acid chain undergoes oxidation and is converted to a carbonyl group to start the cycle all over again. Beta-oxidation is primarily facilitated by the mitochondrial trifunctional protein, an enzyme complex associated with the inner mitochondrial membrane, although very long chain fatty acids are oxidized in peroxisomes. Beta oxidation occurs mainly in the heart, liver and kidney. The overall reaction for one cycle of beta oxidation is:
=== Losses === The bank's deposits increased from $62 billion in March 2020 to $124 billion in March 2021, benefiting from the impact of the COVID-19 pandemic on science and technology. Most of these deposits were invested in long-term Treasury bonds as the bank sought a higher return on investment than was available on shorter-term bonds. These long-term bonds fell in current market value as interest rates rose during the 2021–2023 inflation surge and they became less attractive as investments relative to newer bond issues. In April 2022, SVB's chief risk officer stepped down, and a successor was not named until January 2023—a period coinciding with the period of interest rate increases. At the end of 2022, the bank had a $117 billion bond portfolio, divided into a $91.3 billion held-to-maturity portfolio (meaning it was not marked to market and profits or losses would not be realized until maturity) and a $26 billion available-for-sale portfolio (which as the name implies was marked to market). At that point in time, its marked-to-market unrealized losses for securities held to maturity exceeded $15 billion. The bank did not hedge against interest rate risk on that part of its bond portfolio, apparently for the same reason that most banks do not: the hedge itself would bounce around with the market, while the point of holding bonds to maturity is to hold them at par. Most banks minimize interest rate risk in their held-to-maturity portfolios by buying shorter-term bonds.
Sources: en.wikipedia.org
== Structure and reactivity == Atractyloside is a hydrophilic glycoside. A modified glucose is linked to the hydrophobic diterpene atractyligenin by a β1-glycosidic bond. A carboxyl group is positioned at the C4 position in the axial position. The glucose part is esterified with isovaleric acid on the C2' atom, and sulfuric acid on the C3' and C4' atoms. By hydrolysis a molecule of D-(+)-glucose, isovaleric acid, atractyligenin, and two molecules of sulfuric acid could be obtained. The two sulfate groups and the carboxyl group in ATR are in a deprotonated form under physiological conditions. Thus, ATR is triple negatively charged.
== Participants == The negotiations involved senior political, diplomatic, and security officials from both countries. The United States delegation of nearly 300 members was led by Vice President JD Vance and included senior officials such as special envoy Steve Witkoff and presidential adviser Jared Kushner. According to a senior official cited by BBC News, the broader delegation also included National Security Adviser Andrew Baker and Asian affairs adviser Michael Vance. Additional subject-matter experts were present in Islamabad, with further support teams based in Washington, D.C. The Iranian delegation consisted of around 70 members, led by parliamentary speaker Mohammad Bagher Ghalibaf and Foreign Minister Abbas Araghchi, along with additional political, security, and economic officials. The reported members included:
==== Common causes of chronic wounds ==== Diabetes mellitus – Wound healing impairment in the setting of diabetes is multifactorial. Hyperglycemia, neuropathy, microvascular complications, impaired immune and inflammatory responses, and psychological factors have all been implicated in the formation and propagation of diabetic wounds. Feet are the most common location of diabetic wounds, although any type of wound can be negatively impacted by diabetes. It has been estimated that up to 25% of patients with diabetes mellitus will be affected by non-healing wounds in their lifetime. Venous/Arterial insufficiency – Impaired blood outflow (venous) or inflow (arterial) can both impair wound healing, thereby causing chronic wounds. Much like diabetes, venous/arterial insufficiency most commonly result in chronic wounds of the lower extremities. In chronic venous insufficiency, blood pooling impedes oxygen exchange and creates a chronic pro-inflammatory environment which both promote formation of venous ulcers. Peripheral artery disease, on the other hand, causes wounds due to poor blood inflow and typically affects the most distal extremities (fingers, toes). Immunologic disease – The immune system plays a critical role in the inflammatory process; therefore, any disease of the immune system has the potential to impair the inflammatory phase of wound healing, thereby leading to a chronic wound. Patients suffering from diseases such as rheumatoid arthritis and lupus have been found to have larger wounds and prolonged time to heal when compared to the general population.
Sources: en.wikipedia.org
== Types of nuclear warfare == Nuclear warfare scenarios are usually divided into two groups, each with different effects and potentially fought with different types of nuclear armaments. The first, a limited nuclear war (sometimes attack or exchange), refers to the controlled use of nuclear weapons, whereby the implicit threat exists that a nation can still escalate their use of nuclear weapons. For example, using a small number of nuclear weapons against strictly military targets could be escalated through increasing the number of weapons used, or escalated through the selection of different targets. Limited attacks are thought to be a more credible response against attacks that do not justify all-out retaliation, such as an enemy's limited use of nuclear weapons. The second, a full-scale nuclear war, could consist of large numbers of nuclear weapons used in an attack aimed at an entire country, including military, economic, and civilian targets. Such an attack would almost certainly destroy the entire economic, social, and military infrastructure of the target nation, and would likely have a devastating effect on Earth's biosphere. Some Cold War strategists such as Henry Kissinger argued that a limited nuclear war could be possible between two heavily armed superpowers (such as the United States and the Soviet Union). Some predict, however, that a limited war could potentially "escalate" into a full-scale nuclear war.
By 1988, only five proteins from genetically engineered cells had been approved as drugs by the United States Food and Drug Administration (FDA): synthetic insulin, human growth hormone, hepatitis B vaccine, alpha-interferon, and tissue plasminogen activator (TPa), for lysis of blood clots. By the end of the 1990s, however, 125 more genetically engineered drugs would be approved. The Great Recession led to several changes in the way the biotechnology industry was financed and organized. First, it led to a decline in overall financial investment in the sector, globally; and second, in some countries like the UK it led to a shift from business strategies focused on going for an initial public offering (IPO) to seeking a trade sale instead. By 2011, financial investment in the biotechnology industry started to improve again and by 2014 the global market capitalization reached $1 trillion. Genetic engineering also reached the agricultural front as well. There was tremendous progress since the market introduction of the genetically engineered Flavr Savr tomato in 1994. Ernst and Young reported that in 1998, 30% of the U.S. soybean crop was expected to be from genetically engineered seeds. In 1998, about 30% of the US cotton and corn crops were also expected to be products of genetic engineering. Genetic engineering in biotechnology stimulated hopes for both therapeutic proteins, drugs and biological organisms themselves, such as seeds, pesticides, engineered yeasts, and modified human cells for treating genetic diseases.
== Research == Filorexant was studied for but was not found to be effective in the treatment of diabetic neuropathy, migraine, and major depressive disorder in phase 2 clinical trials. Seltorexant is under development for treatment of major depressive disorder however and is in phase 3 trials for this indication. Also, suvorexant is in a phase 4 trial for use as an adjunct to antidepressant therapy in people with major depressive disorder and residual insomnia.
The number of actions needed to get the drug increases every time, so it becomes harder and harder to get the drug. The highest number of actions that the animal or human is willing to do to get the drug is called the break point. The higher the break point, the more the animal or human wants the drug. In contrast to the classical stimulants such as amphetamine, the effects of modafinil depend on what the animals or humans have to do after getting the drug. If they have to do a performance task, like solving a puzzle or remembering something, modafinil makes them work harder for it than placebo, and the subjects wanted to self-administer modafinil. But if they had to do a relaxation task, like listening to music or watching a video, the subjects did not want to self-administer modafinil. This suggests that modafinil is more rewarding when it helps the animals or humans do something better or faster, especially considering that modafinil is not commonly abused or depended on by people, unlike other stimulants.
Sources: en.wikipedia.org
TB-500 is a name used for a short synthetic peptide fragment taken from the actin-binding region of thymosin beta-4. Material sold under this label is usually a lyophilized powder supplied for laboratory research rather than a licensed medicine. The commonly cited sequence is LKKTETQ.
The parent protein contains forty-three amino acids, while the fragment carries only a short motif from one region. The fragment can interact with actin in vitro, but it does not include the rest of the protein structure. Whether the shorter molecule behaves the same way in living systems is not settled.
Published controlled human studies are scarce, and most activity reports come from cell culture or animal models. Reviews often describe the evidence base as limited and methodologically uneven. Open questions include the relationship between route, dose, and measured outcomes.
No. Thymosin beta-4 is a 43-residue protein, while TB-500 matches only residues 17 to 23 of that chain. The two are related but differ in size, and a method that identifies one does not automatically identify the other.